Vicore Pharma Holding AB (OSTO:VICO BTA) FCF Margin % : -9,653.92% (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Vicore Pharma Holding AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vicore Pharma Holding AB's Free Cash Flow for the three months ended in Mar. 2025 was kr-86.11 Mil. Vicore Pharma Holding AB's Revenue for the three months ended in Mar. 2025 was kr0.89 Mil. Therefore, Vicore Pharma Holding AB's FCF Margin % for the quarter that ended in Mar. 2025 was -9,653.92%.

As of today, Vicore Pharma Holding AB's current FCF Yield % is -15.38%.

The historical rank and industry rank for Vicore Pharma Holding AB's FCF Margin % or its related term are showing as below:

OSTO:VICO BTA' s FCF Margin % Range Over the Past 10 Years
Min: -6896.85 Med: -2432.86 Max: -150.85
Current: -4572.86

During the past 12 years, the highest FCF Margin % of Vicore Pharma Holding AB was -150.85%. The lowest was -6896.85%. And the median was -2432.86%.

OSTO:VICO BTA's FCF Margin % is ranked worse than
89.29% of 999 companies
in the Biotechnology industry
Industry Median: -102.29 vs OSTO:VICO BTA: -4572.86

Vicore Pharma Holding AB FCF Margin % Historical Data

The historical data trend for Vicore Pharma Holding AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB FCF Margin % Chart

Vicore Pharma Holding AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-150.85

Vicore Pharma Holding AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
FCF Margin %	Get a 7-Day Free Trial															22.14	-	-	-1,002.76	-9,653.92

Competitive Comparison of Vicore Pharma Holding AB's FCF Margin %

For the Biotechnology subindustry, Vicore Pharma Holding AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicore Pharma Holding AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Vicore Pharma Holding AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Vicore Pharma Holding AB's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-164.946	/	109.346
	=	-150.85 %

Vicore Pharma Holding AB's FCF Margin for the quarter that ended in Mar. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	-86.113	/	0.892
	=	-9,653.92 %

Vicore Pharma Holding AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO BTA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

VICO:Sweden

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines